A Reversal for Biotelemetry Inc (NASDAQ:BEAT) Is Near. The Stock Has Decrease in Shorts

May 17, 2018 - By Migdalia James

BioTelemetry, Inc. (NASDAQ:BEAT) Logo

Investors sentiment decreased to 0.88 in 2017 Q4. Its down 0.40, from 1.28 in 2017Q3. It worsened, as 47 investors sold BioTelemetry, Inc. shares while 57 reduced holdings. 27 funds opened positions while 65 raised stakes. 27.71 million shares or 8.71% more from 25.49 million shares in 2017Q3 were reported.
Vident Investment Advisory Ltd Company, Georgia-based fund reported 20,471 shares. Renaissance Technologies Llc invested in 560,500 shares or 0.02% of the stock. Glenmede Trust Com Na invested in 1.08 million shares. First Midwest Natl Bank Trust Division holds 0.2% or 52,643 shares in its portfolio. Us National Bank De has invested 0% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Dimensional Fund Advsr L P invested 0.02% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Moreover, Aperio Gru Inc Ltd Liability Co has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Fifth Third National Bank & Trust invested in 21,674 shares or 0% of the stock. Prelude Cap Ltd Co stated it has 63,036 shares or 0.15% of all its holdings. Deutsche Bank Ag has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Tiaa Cref Inv Mngmt Ltd Limited Liability Company holds 0% in BioTelemetry, Inc. (NASDAQ:BEAT) or 168,625 shares. Dubuque Commercial Bank & Tru owns 0.02% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 4,245 shares. Ny State Teachers Retirement reported 14,972 shares. Rothschild Asset Mngmt Incorporated owns 54,350 shares or 0.02% of their US portfolio. The Tennessee-based State Of Tennessee Treasury Department has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT).

The stock of Biotelemetry Inc (NASDAQ:BEAT) registered a decrease of 5.43% in short interest. BEAT’s total short interest was 3.26M shares in May as published by FINRA. Its down 5.43% from 3.45M shares, reported previously. With 419,000 shares average volume, it will take short sellers 8 days to cover their BEAT’s short positions. The short interest to Biotelemetry Inc’s float is 10.31%.

The stock increased 0.86% or $0.35 during the last trading session, reaching $41.15. About 165,592 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 11.39% since May 17, 2017 and is uptrending. It has underperformed by 0.16% the S&P500.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.35 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It currently has negative earnings. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Among 2 analysts covering BioTelemetry (NASDAQ:BEAT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 2 analyst reports since November 30, 2017 according to SRatingsIntel. Dougherty maintained BioTelemetry, Inc. (NASDAQ:BEAT) rating on Friday, February 23. Dougherty has “Buy” rating and $41.0 target. The company was maintained on Thursday, November 30 by Raymond James.

More recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Seekingalpha.com which released: “BioTelemetry’s (BEAT) CEO Joseph Capper on Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. Globenewswire.com‘s news article titled: “BioTelemetry, Inc. Reports First Quarter 2018 Financial Results” with publication date: April 25, 2018 was also an interesting one.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.